Full Press Release Details
CryoPort Names Karen M. Muller to
May 31, 2011 - CryoPort, Inc. (OTCBB: CYRX) today announced that
it has named Karen M. Muller to its Board of Directors. Ms. Muller, 56, is
a corporate attorney with more than 25 years of experience as both a
company executive and legal counsel. She will serve as an independent director,
giving CryoPort three independent directors.
"Karen has a proven record of
building and managing successful organizations, and she is an outstanding
addition to our board," said Larry Stambaugh, CryoPort's Chairman
and Chief Executive Officer. "Her management skills, knowledge of the
healthcare industry, and experience in financial transactions will play an
important role in shaping strategy and guiding our growth."
Ms. Muller currently manages a
private practice with clients in the healthcare, pharmaceutical, and medical
device industries. She recently served as a Director and consultant to
Naturade, a leading nutrition and nutraceutical company. Previously, she was
Chief Administrative Officer and General Counsel of Epoch Networks, where she
helped complete the restructuring and sale of Epoch's Internet Service
Provider business, the largest privately held ISP in the country.
Prior to joining Epoch,
Ms. Muller was a Managing Director with Lehman Brothers, heading the
corporate counsel department. Earlier she was an associate at the Wall Street
law firm Cahill, Gordon & Reindel, where she worked on corporate finance
and mergers and acquisitions.
Ms. Muller graduated Fordham
Law School in 1981, where she was a published member of the law review. She
received her bachelor's degree in economics, summa cum laude, from Hunter
College of the City University of New York. She also holds the title Director
Emeritus with the Forum for Corporate Directors in Orange County, California.
About CryoPort, Inc.
CryoPort (www.cryoport.com)
has developed a leading edge, proprietary, technology-driven transport and
packaging system focused on providing a solution that replaces dry ice for the
frozen shipping market in the growing global life science industry. The
products developed by CryoPort have a 10+ day holding time, are using
"green" materials and are essential components of the
infrastructure required for the testing, research and end-user delivery of
temperature-sensitive medicines and biomaterials in an increasingly complex
global logistical environment.
Forward Looking Statements
Statements in this press release
which are not purely historical, including statements regarding CryoPort,
Inc.'s intentions, hopes, beliefs, expectations, representations,
projections, plans or predictions of the future are forward-looking statements
within the meaning of the Private Securities Litigation Reform Act of 1995. It
is important to note that the company's actual results could differ
materially from those in any such forward-looking statements. Factors that
could cause actual results to differ materially include, but are not limited
to, risks and uncertainties associated with the effect of changing economic
conditions, trends in the products markets, variations in the company's
cash flow, market acceptance risks, and technical development risks. The
company's business could be affected by a number of other factors,
including the risk factors listed from time to time in the company's SEC
reports including, but not limited to, the annual report on Form
10-K for the year ended March 31, 2010. The company cautions
investors not to place undue reliance on the forward-looking statements
contained in this press release. CryoPort, Inc. disclaims any obligation, and
does not undertake to update or revise any forward-looking statements in this
Lippert/Heilshorn & Associates